Pharmafile Logo

Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.

In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision.

Following Genesis Research Group’s recent expansion of its real-world data analytics capabilities and the appointment of Ki Park as VP, Market Access Strategy & Analytics, the innovative global HEOR, access & pricing and real-world evidence research organization has fully outlined its integrated market access offering.

Genesis Research Group A&P image

Genesis Research Group leverages its proprietary RPR stakeholder engagement platform, a network of 3,500+ vetted payers, clinicians, and KOLs across 65 countries, coupled with deep expertise in access, pricing, HEOR, and real-world analytics, to deliver end-to-end solutions that drive commercial success.

Each of the following capabilities can be integrated to boost results or applied independently—helping clients to transform complex challenges throughout the product lifecycle into competitive advantages.

✅ Global strategic advisory
Navigate complex US and global challenges with clarity and confidence. The company’s experts partner with you to develop detailed strategies on product positioning, pricing, and value demonstration – maximizing commercial success through tailored, market-specific solutions.

✅ US data-driven analytics
Navigate the evolving US market landscape with advanced analytical solutions, from contracting strategy and product adoption to LOE analysis, co pay optimization, and IRA impact assessment. This end-to-end approach delivers robust, actionable insights that drive measurable results.

✅ RPR stakeholder insights
Empower strategic access and pricing decisions with RPR, a proprietary stakeholder engagement platform. Gain actionable and pressure-tested insights from 3,500+ vetted payers, clinicians, and KOLs across 65 countries – delivered faster and more robustly than traditional primary research methods.

✅ Analogue and landscape research
Establish strategic clarity through rigorous analogue lookbacks and detailed landscape assessments. Tailored secondary research servoces deliver precise benchmarking on pricing, reimbursement decisions, and HTA outcomes – seamlessly integrated with access and pricing, HEOR, and evidence generation expertise to reduce uncertainty and inform effective decision-making.

✅ A&P Flexible Integrated Teams (FIT)
Benefit from adaptable contracting models tailored to your specific needs, or build an agile, extended partnership with an innovative Access & Pricing FIT (Flexible Integrated Team) engagement for long-term strategic collaboration.

Visit Genesisrg.com to find out more, or contact solutions@genesisrg.com to ask how they can help you overcome your challenges.

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will…

On GLOBE Final Rule

The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally….

Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.

On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.

Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…

Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview

At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…

Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…

ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…